Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

IL-17 Responses Are the Dominant Inflammatory Signal Linking Inverse, Erythrodermic, and Chronic Plaque Psoriasis.

Xing X, Liang Y, Sarkar MK, Wolterink L, Swindell WR, Voorhees JJ, Harms PW, Kahlenberg JM, Johnston A, Gudjonsson JE.

J Invest Dermatol. 2016 Dec;136(12):2498-2501. doi: 10.1016/j.jid.2016.07.008. Epub 2016 Jul 21. No abstract available.

2.

Clinical Efficiency of Topical Calcipotriol/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory TNFα - IL-23 - IL-17 Axis.

Kubin ME, Kokkonen N, Palatsi R, Hägg PM, Väyrynen JP, Glumoff V, Haapasaari KM, Hurskainen T, Tasanen K.

Acta Derm Venereol. 2017 Apr 6;97(4):449-455. doi: 10.2340/00015555-2579.

3.

Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis.

Moy AP, Murali M, Kroshinsky D, Duncan LM, Nazarian RM.

JAMA Dermatol. 2015 Jul;151(7):753-60. doi: 10.1001/jamadermatol.2015.2.

PMID:
25760640
4.

Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.

Koutsoukou XA, Papadavid E, Theodoropoulos K, Rigopoulos D.

Dermatol Ther. 2014 Sep-Oct;27(5):257-9. doi: 10.1111/dth.12131. Epub 2014 May 9.

PMID:
24813816
5.

Tyk2 is a therapeutic target for psoriasis-like skin inflammation.

Ishizaki M, Muromoto R, Akimoto T, Sekine Y, Kon S, Diwan M, Maeda H, Togi S, Shimoda K, Oritani K, Matsuda T.

Int Immunol. 2014 May;26(5):257-67. doi: 10.1093/intimm/dxt062. Epub 2013 Dec 17.

6.

Role of IL-17A signalling in psoriasis and associated bone loss.

Uluçkan Ö, Wagner EF.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):17-20. Epub 2016 Jul 20. Review.

7.

Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis.

Kakeda M, Schlapbach C, Danelon G, Tang MM, Cecchinato V, Yawalkar N, Uguccioni M.

Arch Dermatol Res. 2014 Dec;306(10):933-8. doi: 10.1007/s00403-014-1488-0. Epub 2014 Jul 17.

PMID:
25030504
8.

Erythrodermic psoriasis peculiarly sparing anti-TNF injection sites in a patient with secondary loss of efficacy.

Kapoor DM, Tan KW.

Dermatol Ther. 2017 Nov;30(6). doi: 10.1111/dth.12551. Epub 2017 Oct 4. No abstract available.

PMID:
28976682
9.

IL-17 for therapy.

Kurschus FC, Moos S.

J Dermatol Sci. 2017 Sep;87(3):221-227. doi: 10.1016/j.jdermsci.2017.06.010. Epub 2017 Jun 15. Review.

PMID:
28633806
10.

Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis.

van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E.

J Immunol. 2009 May 1;182(9):5836-45. doi: 10.4049/jimmunol.0802999.

11.

TNF, but not IL-6 and IL-17, is crucial for the development of T cell-independent psoriasis-like dermatitis in Il1rn-/- mice.

Nakajima A, Matsuki T, Komine M, Asahina A, Horai R, Nakae S, Ishigame H, Kakuta S, Saijo S, Iwakura Y.

J Immunol. 2010 Aug 1;185(3):1887-93. doi: 10.4049/jimmunol.1001227. Epub 2010 Jul 7.

12.

LL-37 attenuates inflammatory impairment via mTOR signaling-dependent mitochondrial protection.

Sun W, Zheng Y, Lu Z, Wang H, Feng Z, Wang J, Xiao S, Liu F, Liu J.

Int J Biochem Cell Biol. 2014 Sep;54:26-35. doi: 10.1016/j.biocel.2014.06.015. Epub 2014 Jun 28.

PMID:
24984264
13.

mTORC2-PKBα/Akt1 Serine 473 phosphorylation axis is essential for regulation of FOXP3 Stability by chemokine CCL3 in psoriasis.

Chen L, Wu J, Pier E, Zhao Y, Shen Z.

J Invest Dermatol. 2013 Feb;133(2):418-28. doi: 10.1038/jid.2012.333. Epub 2012 Dec 6.

14.

Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies.

Ram-Wolff C, Martin-Garcia N, Bensussan A, Bagot M, Ortonne N.

Am J Dermatopathol. 2010 Dec;32(8):755-63. doi: 10.1097/DAD.0b013e3181cfbfbf.

15.

Interleukin-36γ (IL-1F9) Identifies Psoriasis Among Patients With Erythroderma.

Braegelmann J, D Erme AM, Akmal S, Maier J, Braegelmann C, Wenzel J.

Acta Derm Venereol. 2016 Mar;96(3):386-7. doi: 10.2340/00015555-2265. No abstract available.

16.

An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling.

El Malki K, Karbach SH, Huppert J, Zayoud M, Reissig S, Schüler R, Nikolaev A, Karram K, Münzel T, Kuhlmann CR, Luhmann HJ, von Stebut E, Wörtge S, Kurschus FC, Waisman A.

J Invest Dermatol. 2013 Feb;133(2):441-51. doi: 10.1038/jid.2012.318. Epub 2012 Sep 6.

17.
18.

Multi-glycoside of Tripterygium wilfordii Hook. f. ameliorates imiquimod-induced skin lesions through a STAT3-dependent mechanism involving the inhibition of Th17-mediated inflammatory responses.

Zhao J, Di T, Wang Y, Liu X, Liang D, Zhang G, Li P.

Int J Mol Med. 2016 Sep;38(3):747-57. doi: 10.3892/ijmm.2016.2670. Epub 2016 Jul 11.

19.

Stem cells in psoriasis.

Hou R, Li J, Niu X, Liu R, Chang W, Zhao X, Wang Q, Li X, Yin G, Zhang K.

J Dermatol Sci. 2017 Jun;86(3):181-186. doi: 10.1016/j.jdermsci.2016.11.006. Epub 2016 Nov 15. Review.

PMID:
27894778
20.

Dysregulation of miRNA146a versus IRAK1 induces IL-17 persistence in the psoriatic skin lesions.

Xia P, Fang X, Zhang ZH, Huang Q, Yan KX, Kang KF, Han L, Zheng ZZ.

Immunol Lett. 2012 Dec 17;148(2):151-62. doi: 10.1016/j.imlet.2012.09.004. Epub 2012 Sep 24.

PMID:
23018031

Supplemental Content

Support Center